Merck’s Lagevrio Receives Emergency Conditional Approval from China’s NMPA
US-based Merck, Sharp & Dohme Inc. (MSD; NYSE: MRK) has announced receiving emergency conditional approval...
NHSA and CNIPA Issue Opinions on Strengthening IP Protection in Drug Procurement
The National Healthcare Security Administration (NHSA) and the China National Intellectual Property Administration (CNIPA) have...
Legend Biotech’s Carvykti Accepted for Review by China’s CDE
The Center for Drug Evaluation (CDE) website indicates that a market approval filing from Legend...
F-star Therapeutics and Sino Biopharmaceutical Face Delays in Proposed Acquisition
UK-based biotech F-star Therapeutics (NASDAQ: FSTX) released an SEC filing indicating that the proposed acquisition...
CSPC’s ALMB-0168 Receives NMPA Approval for Osteoarthritis Clinical Study
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced receiving approval from the National Medical...
RemeGen’s RC108 Receives FDA Go-Ahead for Phase I Clinical Study
China-based biopharma RemeGen Ltd (HKG: 9995) has announced receiving approval from the US FDA to...
Simcere Receives NMPA Clearance for SIM0348 Clinical Study
China-based Simcere Pharmaceutical Group (HKG: 2096) has announced receiving clearance from the National Medical Products...
Skynor Medical Raises RMB 100 Million in Financing Round for Market Expansion
Skynor Medical, a Shanghai-based manufacturer of nerve and peripheral blood vessel implantation and interventional devices,...
Sichuan Kelun Completes RMB 1.5 Billion Financing Round for Kelun-Biotech
China-based Sichuan Kelun Pharmaceutical Co., Ltd (SHE: 002422) has announced the completion of a financing...
Everest Medicines’ Nefecon Receives Priority Review Recommendation from CDE
China-based Everest Medicines (HKG: 1952) has announced that the Center for Drug Evaluation (CDE) of...
BrightGene Receives NMPA Approval for BGM0504 Clinical Trial
China-based BrightGene Bio-Medical Technology Co., Ltd (SHA: 688166) has announced that it has received clinical...
Anhui Anke Biotechnology Receives NMPA Approval for AK2017 Clinical Study
China-based Anhui Anke Biotechnology (Group) Co., Ltd (SHE: 300009) has announced receiving approval from the...
AstraZeneca’s Nexium Approved by NMPA for Adolescent GERD Treatment
UK-based pharmaceutical major AstraZeneca (NASDAQ: AZN) has announced receiving market approval from the National Medical...
Sino Biopharmaceutical Secures Rights to Shionogi’s COVID-19 Therapy Ensitrelvir
China-based Sino Biopharmaceutical Ltd (HKG: 1177) has announced that its subsidiary Jiangsu Chia Tai Tianqing...
Shenzhen Core Medical Raises ‘Hundreds of Millions’ in Series C Financing
Shenzhen-based heart failure mechanical circulatory support solutions provider, Shenzhen Core Medical Technology Co., Ltd, has...
Sinovac Reports H1 2022 Financials Amid COVID-19 Vaccine Demand Decline
China-based Sinovac Biotech Ltd (NASDAQ: SVA) has released its financial report for the first half...
Junshi Biosciences’ JT001 (VV116) Shows Non-Inferiority to Paxlovid in COVID-19 Trial
The results of a Phase III clinical study for China-based Junshi Biosciences’ (HKG: 1877, SHA:...
Hainan Shuangcheng Files Paragraph IV Patent Declaration for Paclitaxel, Albumin-Bound
China’s Hainan Shuangcheng Pharmaceutical Co., Ltd (SHE: 002693) has announced a Paragraph IV patent declaration...
Grand Pharma’s COVID-19 Therapy GS221 Shows Promising Safety Profile
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that its clinical study for the...
Fosun Pharma Launches Online Registration for BioNTech COVID-19 Vaccine in Hong Kong
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced a new initiative...